Patent classifications
C12Y103/08001
Bacteria Engineered to Treat Diseases that Benefit from Reduced Gut Inflammation and/or Tightened Gut Mucosal Barrier
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
Bacteria Engineered to Treat Diseases that Benefit from Reduced Gut Inflammation and/or Tighten Gut Mucosal Barrier
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
BACTERIA ENGINEERED TO TREAT DISEASES THAT BENEFIT FROM REDUCED GUT INFLAMMATION AND/OR TIGHTENED GUT MUCOSAL BARRIER
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
BACTERIA ENGINEERED TO TREAT DISEASES THAT BENEFIT FROM REDUCED GUT INFLAMMATION AND/OR TIGHTENED GUT MUCOSAL BARRIER
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
ORGANISMS PRODUCING LESS CROTONIC ACID
The present invention relates to a recombinant organism or microorganism having a decreased pool of crotonic acid compared to the organism or microorganism from which it is derived due to at least one of: (i) an increased conversion of crotonyl-CoA into butyryl-CoA; and/or an increased conversion of butyryl-CoA into butyric acid; (ii) an increased conversion of crotonyl-CoA into 3-hydroxybutyryl-CoA; and/or an increased conversion of 3-hydroxybutyryl-CoA into 3-hydroxybutyric acid; (iii) an increased conversion of crotonic acid into crotonyl-CoA; (iv) an increased conversion of crotonyl-[acyl-carrier protein] into butyryl [acyl-carrier-protein]; (v) a decreased conversion of crotonyl-CoA into crotonic acid; and/or (vi) a decreased conversion of crotonyl-[acyl-carrier protein] into crotonic acid. Moreover, the present invention relates to the use of such a recombinant organism or microorganism for the production of alkenes with the enzyme ferulic acid decarboxylase. Further, the present invention relates to a method for the production of isobutene or butadiene by culturing such a recombinant organism or microorganism in a suitable culture medium under suitable conditions.
ENZYMES, CELLS, AND METHODS FOR PRODUCING CIS-3 HEXENOL
The present disclosure relates, in part, to microbial hosts capable of synthesizing cis-3-hexenol, cis-3-hexenal, trans-3-hexenol, trans-3-hexenal, trans-2-hexenal, cis-2-hexenal and related compounds from hexanoic acid and methods for the preparation of cis-3-hexenol, cis-3-hexenal, trans-3-hexenol, trans-3-hexenal, trans-2-hexenal, cis-2-hexenal and related compounds.